Skip to content
How It Works
Explore
Ask a Question Resources Pricing
Who It's For
Patients
Decode results, prep for appointments, weigh options.
Caregivers & advocates
Carry the research load for someone you love.
Providers & clinicians
Resources for patients in your practice.
Log In Sign Up
PubMed This is a summary of 23 peer-reviewed journal articles Updated
Endocrinology · Familial Partial Lipodystrophy Type 3

Standard of Care Treatment

At a Glance

FPLD3 treatment combines an individualized diet and activity plan with medicines for high triglycerides, diabetes, and insulin resistance. Fibrates, omega-3s, metformin, insulin, and specialist therapies such as metreleptin may help reduce pancreatitis and other metabolic risks.

Managing Familial Partial Lipodystrophy Type 3 (FPLD3) requires a proactive approach to prevent “ectopic fat” complications—the damage caused when fat spills over into your blood, liver, and muscles because it cannot be stored safely under your skin [1][2]. Treatment focuses on controlling two main metabolic issues: severe hypertriglyceridemia (very high blood fats) and insulin resistance (diabetes) [3]. Crucially, never start, stop, or drastically change your medications or diet without consulting your treating clinician.

The Foundation: Nutrition and Lifestyle

Diet is a critical tool for managing FPLD3. Because your body has a limited capacity to store lipids, you must carefully manage the “fuel” you put in [1].

  • Individualized Fat Management: If your triglycerides are dangerously high, you may need to strictly limit dietary fat, which requires individualized guidance from a registered dietitian [4][5]. In extreme cases (such as after a bout of pancreatitis), doctors may temporarily recommend a very-low-fat diet [6][7]. However, extreme fat restriction without professional supervision can lead to nutrient deficiencies and may unintentionally worsen triglycerides if replaced with refined carbohydrates.
  • Alcohol Avoidance: Alcohol can significantly worsen hypertriglyceridemia and increase the risk of pancreatitis. Complete avoidance is often recommended for patients with high lipid levels, along with limiting rapidly absorbed, refined carbohydrates [5][8].
  • Physical Activity: Regular exercise helps your muscles burn excess fat and sugar, improving insulin sensitivity. Your care team should help you create an individualized plan based on your current fitness and any other health conditions [9][2].

Managing Severe Triglycerides

The primary goal of lipid management is to prevent acute pancreatitis, a painful and dangerous inflammation of the pancreas [7].

  • Fibrates and Omega-3s: Fibrates (like fenofibrate) are typically the first line of defense for lowering triglycerides [3][8]. Prescription-strength omega-3 fatty acids may also be added to help reduce lipid levels [10][11].
  • Addressing Secondary Factors: Many common factors can “spike” your triglycerides. Your doctor should review your medications for drugs that raise lipids (like certain diuretics or estrogens) and ensure your blood sugar is well-controlled, as high sugar levels drive up triglycerides [8][12].
  • Statins: While fibrates target triglycerides, statins are established standard care used to lower your overall cardiovascular risk and manage LDL (“bad”) cholesterol [10][13].

Diabetes and Insulin Resistance

Because FPLD3 causes severe insulin resistance, standard diabetes treatments are often needed in higher doses or combinations [14].

  • First-Line Options: Metformin is frequently the starting point for improving how your body uses insulin [10]. If blood sugar remains high, insulin may be required [15].
  • Thiazolidinediones (TZDs): In some FPLD3 patients, a specialist may trial TZDs like pioglitazone to improve blood sugar, triglycerides, and even help restore regular menstrual cycles [16][17]. However, genotype-directed response is highly variable and they carry significant risks like fluid retention, weight gain, worsened heart failure, or fractures, so they must be used carefully [18][19].
  • Emerging Therapies: Newer classes of drugs like GLP-1 receptor agonists (e.g., semaglutide) and SGLT2 inhibitors (e.g., empagliflozin) are increasingly used off-label as “add-on” treatments. They have shown promise in lowering HbA1c and triglycerides in people with partial lipodystrophy [20][21]. However, they require careful individualization: GLP-1s require review of your pancreatitis history, and SGLT2 inhibitors carry a risk of euglycemic ketoacidosis (a dangerous blood acid imbalance), particularly during illness, fasting, or restrictive diets.

Specialized Treatments

For patients with very low levels of leptin (a hormone produced by fat tissue) and severe metabolic disease that doesn’t respond to standard care, a specialized treatment called metreleptin may be considered [10]. In FPLD3 patients, it has been shown to reduce insulin requirements and improve blood sugar control [22][23]. This treatment is typically managed by lipodystrophy specialists [23].

Common questions in this guide

How is FPLD3 usually treated?
Treatment combines an individualized nutrition and activity plan with medicines that address high triglycerides and insulin resistance. The goals are to lower the risk of pancreatitis, improve blood sugar, and reduce complications from fat building up in organs and muscles.
Which medicines can lower triglycerides in FPLD3?
Fibrates such as fenofibrate are commonly used first to lower triglycerides, and prescription omega-3 fatty acids may be added. Statins may also be used to lower LDL cholesterol and overall cardiovascular risk, while blood sugar, alcohol use, and other medicines that raise triglycerides should be reviewed.
What diabetes treatments may be used for FPLD3?
Metformin is often used first, but severe insulin resistance may require insulin or combinations of medicines. A specialist may consider pioglitazone, a GLP-1 receptor agonist, or an SGLT2 inhibitor in selected patients, with attention to each treatment’s risks and the person’s medical history.
Could pioglitazone help if I have a PPARG variant?
Some people with FPLD3 may have improved blood sugar or triglycerides with pioglitazone, but response can vary by genetic variant. It can also cause fluid retention, weight gain, worsening heart failure, or fractures, so a specialist should weigh the potential benefits and risks.
When should I seek urgent advice about pancreatitis?
Very high triglycerides increase the risk of acute pancreatitis. Persistent upper abdominal pain or nausea should prompt urgent medical advice, and your clinician can tell you the triglyceride level and symptoms that require immediate action.
When might metreleptin be considered for FPLD3?
Metreleptin may be considered by a lipodystrophy specialist when leptin levels are very low and severe metabolic problems remain uncontrolled despite standard treatment. In FPLD3, it may reduce insulin requirements and improve blood sugar control.

Questions For You

Answer a question to get research tailored to you. Your answers are private.

Get notified when new evidence is published on PPARG-related familial partial lipodystrophy.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.Based on my specific PPARG variant, is there evidence that I might respond better to pioglitazone (a TZD)?
  2. 2.What is my fasting triglyceride goal to minimize my risk of pancreatitis, and at what number should I call for urgent advice?
  3. 3.Are any of my current medications (like certain blood pressure drugs or hormones) making my triglycerides higher?
  4. 4.Is a GLP-1 receptor agonist or an SGLT2 inhibitor a safe and appropriate next step for my blood sugar and weight management?
  5. 5.What is my current leptin level, and should we consider applying for metreleptin if my metabolic issues remain uncontrolled?

References

References (23)
  1. 1

    Familial Partial Lipodystrophy (FPLD): Recent Insights.

    Bagias C, Xiarchou A, Bargiota A, Tigas S

    Diabetes, metabolic syndrome and obesity : targets and therapy 2020; (13()):1531-1544 doi:10.2147/DMSO.S206053.

    PMID: 32440182
  2. 2

    Partial lipodystrophy: Clinical presentation and treatment.

    Mosbah H, Vatier C, Vigouroux C

    Annales d'endocrinologie 2024; (85(3)):197-200 doi:10.1016/j.ando.2024.05.015.

    PMID: 38871513
  3. 3

    Advances in the care of lipodystrophies.

    Shamsudeen I, Hegele RA

    Current opinion in endocrinology, diabetes, and obesity 2022; (29(2)):152-160 doi:10.1097/MED.0000000000000695.

    PMID: 34839327
  4. 4

    A subset of patients with acquired partial lipodystrophy developing severe metabolic abnormalities.

    Ozgen Saydam B, Sonmez M, Simsir IY, et al.

    Endocrine research 2019; (44(1-2)):46-54 doi:10.1080/07435800.2018.1513029.

    PMID: 30182761
  5. 5

    Approach to the Adult Patient with Chylomicronemia.

    Hegele RA

    The Journal of clinical endocrinology and metabolism 2026; (111(3)):845-859 doi:10.1210/clinem/dgaf701.

    PMID: 41472374
  6. 6

    Volanesorsen in the Treatment of Familial Chylomicronemia Syndrome or Hypertriglyceridaemia: Design, Development and Place in Therapy.

    Esan O, Wierzbicki AS

    Drug design, development and therapy 2020; (14()):2623-2636 doi:10.2147/DDDT.S224771.

    PMID: 32753844
  7. 7

    Genotype - phenotype correlation in an adolescent girl with pathogenic PPARy genetic variation that caused severe hypertriglyceridemia and early onset type 2 diabetes.

    Gutierrez Alvarez A, Yachelevich N, Kohn B, Brar PC

    Annals of pediatric endocrinology & metabolism 2021; (26(4)):284-289 doi:10.6065/apem.2142056.028.

    PMID: 34991302
  8. 8

    A Comprehensive Update on the Chylomicronemia Syndrome.

    Goldberg RB, Chait A

    Frontiers in endocrinology 2020; (11()):593931 doi:10.3389/fendo.2020.593931.

    PMID: 33193106
  9. 9

    Monogenic forms of lipodystrophic syndromes: diagnosis, detection, and practical management considerations from clinical cases.

    Vatier C, Vantyghem MC, Storey C, et al.

    Current medical research and opinion 2019; (35(3)):543-552 doi:10.1080/03007995.2018.1533459.

    PMID: 30296183
  10. 10

    The Diagnosis and Management of Lipodystrophy Syndromes: A Multi-Society Practice Guideline.

    Brown RJ, Araujo-Vilar D, Cheung PT, et al.

    The Journal of clinical endocrinology and metabolism 2016; (101(12)):4500-4511 doi:10.1210/jc.2016-2466.

    PMID: 27710244
  11. 11

    First diagnosis of familial partial lipodystrophy syndrome type 3 during pregnancy associated with a novel heterozygous PPARG variant and a concurrent ABCC8 variant: a case report.

    Holstein A, Jabri I, Linck JA, et al.

    Frontiers in endocrinology 2026; (17()):1855679 doi:10.3389/fendo.2026.1855679.

    PMID: 42440509
  12. 12

    Prevalence of severe hypertriglyceridemia and pancreatitis in familial partial lipodystrophy type 2.

    Lazarte J, Wang J, McIntyre AD, Hegele RA

    Journal of clinical lipidology 2021; (15(5)):653-657 doi:10.1016/j.jacl.2021.07.004.

    PMID: 34340952
  13. 13

    Hypertriglyceridemia.

    Chait A

    Endocrinology and metabolism clinics of North America 2022; (51(3)):539-555 doi:10.1016/j.ecl.2022.02.010.

    PMID: 35963627
  14. 14

    Familial partial lipodystrophy, Dunnigan variety - challenges for patient care during pregnancy: a case report.

    Belo SP, Magalhães ÂC, Freitas P, Carvalho DM

    BMC research notes 2015; (8()):140 doi:10.1186/s13104-015-1065-4.

    PMID: 25885670
  15. 15

    Lipodystrophy for the Diabetologist-What to Look For.

    Patni N, Garg A

    Current diabetes reports 2022; (22(9)):461-470 doi:10.1007/s11892-022-01485-w.

    PMID: 35821558
  16. 16

    Systematic review of genotype-stratified treatment for monogenic insulin resistance.

    Semple RK, Patel KA, Auh S, et al.

    medRxiv : the preprint server for health sciences 2023; doi:10.1101/2023.04.17.23288671.

    PMID: 37205502
  17. 17

    Familial partial lipodystrophy linked to a novel peroxisome proliferator activator receptor -γ (PPARG) mutation, H449L: a comparison of people with this mutation and those with classic codon 482 Lamin A/C (LMNA) mutations.

    Demir T, Onay H, Savage DB, et al.

    Diabetic medicine : a journal of the British Diabetic Association 2016; (33(10)):1445-50 doi:10.1111/dme.13061.

    PMID: 26756202
  18. 18

    Lobeglitazone: A Novel Thiazolidinedione for the Management of Type 2 Diabetes Mellitus.

    Bae J, Park T, Kim H, et al.

    Diabetes & metabolism journal 2021; (45(3)):326-336 doi:10.4093/dmj.2020.0272.

    PMID: 33866775
  19. 19

    A Pharmacogenetic Approach to the Treatment of Patients With PPARG Mutations.

    Agostini M, Schoenmakers E, Beig J, et al.

    Diabetes 2018; (67(6)):1086-1092 doi:10.2337/db17-1236.

    PMID: 29622583
  20. 20

    Safety and effectiveness in an uncontrolled setting of glucagon-like-peptide-1 receptor agonists in patients with familial partial lipodystrophy: Real-life experience from a national reference network.

    Lamothe S, Belalem I, Vantyghem MC, et al.

    Diabetes, obesity & metabolism 2025; (27(4)):1815-1825 doi:10.1111/dom.16175.

    PMID: 39829337
  21. 21

    Metabolic effects of pioglitazone and sodium-glucose cotransporter 2 inhibitors in familial partial lipodystrophy.

    Soyaltin U, Simsir IY, Akinci B

    Acta diabetologica 2026; (63(3)):497-505 doi:10.1007/s00592-025-02633-w.

    PMID: 41369773
  22. 22

    Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants.

    Sekizkardes H, Cochran E, Malandrino N, et al.

    The Journal of clinical endocrinology and metabolism 2019; (104(8)):3068-3076 doi:10.1210/jc.2018-02787.

    PMID: 31194872
  23. 23

    Partial and generalized lipodystrophy: comparison of baseline characteristics and response to metreleptin.

    Diker-Cohen T, Cochran E, Gorden P, Brown RJ

    The Journal of clinical endocrinology and metabolism 2015; (100(5)):1802-10 doi:10.1210/jc.2014-4491.

    PMID: 25734254

This page explains treatment options for PPARG-related FPLD3 for informational purposes and does not constitute medical advice. Work with your treating clinician or a lipodystrophy specialist before changing medications, diet, or exercise.